JP2023546361A - ループスにおける紅斑の治療 - Google Patents

ループスにおける紅斑の治療 Download PDF

Info

Publication number
JP2023546361A
JP2023546361A JP2023521356A JP2023521356A JP2023546361A JP 2023546361 A JP2023546361 A JP 2023546361A JP 2023521356 A JP2023521356 A JP 2023521356A JP 2023521356 A JP2023521356 A JP 2023521356A JP 2023546361 A JP2023546361 A JP 2023546361A
Authority
JP
Japan
Prior art keywords
patient
anifrolumab
patients
sle
bilag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521356A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022074123A5 (https=
JP2023546361A5 (https=
Inventor
カルヤニ，ルバナ
アブレウ，ガブリエル
トゥマラ，ラジェンドラ
フュリー，リチャード
モランド，エリック
アスカナセ，アンカ
ビタル，エド
カルニアン，ケネス
リンドホルム，カタリーナ
マオ，エマニュエル
クレウディス，クリスティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023546361A publication Critical patent/JP2023546361A/ja
Publication of JPWO2022074123A5 publication Critical patent/JPWO2022074123A5/ja
Publication of JP2023546361A5 publication Critical patent/JP2023546361A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
JP2023521356A 2020-10-08 2021-10-07 ループスにおける紅斑の治療 Pending JP2023546361A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063089355P 2020-10-08 2020-10-08
US63/089,355 2020-10-08
US202163178748P 2021-04-23 2021-04-23
US63/178,748 2021-04-23
PCT/EP2021/077702 WO2022074123A1 (en) 2020-10-08 2021-10-07 Treatment of flares in lupus

Publications (3)

Publication Number Publication Date
JP2023546361A true JP2023546361A (ja) 2023-11-02
JPWO2022074123A5 JPWO2022074123A5 (https=) 2024-09-24
JP2023546361A5 JP2023546361A5 (https=) 2024-09-24

Family

ID=78269610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521356A Pending JP2023546361A (ja) 2020-10-08 2021-10-07 ループスにおける紅斑の治療

Country Status (11)

Country Link
US (1) US20240026015A1 (https=)
EP (1) EP4225791A1 (https=)
JP (1) JP2023546361A (https=)
KR (1) KR20230082659A (https=)
CN (1) CN116406296A (https=)
AU (1) AU2021356122B2 (https=)
BR (1) BR112023006328A2 (https=)
CA (1) CA3197055A1 (https=)
IL (1) IL301759A (https=)
TW (1) TW202237647A (https=)
WO (1) WO2022074123A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
BR112023021868A2 (pt) * 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
EP4587005A1 (en) 2022-09-14 2025-07-23 Viatris Asia Pacific Pte. Ltd. Sip 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
EP2687232A1 (en) * 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
KR102766960B1 (ko) * 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) * 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
2019 ACR/ARP ANNUAL MEETING, JPN6025043083, November 2019 (2019-11-01), pages 1763, ISSN: 0005712007 *
2019 ACR/ARP ANNUAL MEETING, JPN6025043084, October 2019 (2019-10-01), pages 17, ISSN: 0005712006 *
LANCET RHEUMATOL., vol. Vol.1, Issue 4, JPN6025043085, December 2019 (2019-12-01), pages 208 - 219, ISSN: 0005712005 *
N． ENGL. MED., vol. 382, no. 3, JPN6025043086, January 2020 (2020-01-01), pages 211 - 221, ISSN: 0005828743 *

Also Published As

Publication number Publication date
BR112023006328A2 (pt) 2023-05-09
TW202237647A (zh) 2022-10-01
AU2021356122A1 (en) 2023-06-08
CA3197055A1 (en) 2022-04-14
KR20230082659A (ko) 2023-06-08
IL301759A (en) 2023-05-01
CN116406296A (zh) 2023-07-07
US20240026015A1 (en) 2024-01-25
AU2021356122B2 (en) 2026-02-05
WO2022074123A1 (en) 2022-04-14
EP4225791A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
AU2021356122B2 (en) Treatment of flares in lupus
JP7805393B2 (ja) 皮下注射のための抗ｉｆｎａｒ１投薬計画
KR20220099985A (ko) 전신성 홍반성 루푸스에서 i형 인터페론 억제
JP2024516886A (ja) 全身性エリテマトーデス患者における１型インターフェロン受容体阻害剤のステロイド節約
KR20240038773A (ko) 루푸스의 치료
JP2024536320A (ja) ループスの処置
JP2025533978A (ja) ループスの治療
EP4713361A1 (en) Treatment of lupus
EA052183B1 (ru) Лечение кожной красной волчанки
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制
CN117677638A (zh) 狼疮的治疗
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
EA047082B1 (ru) Схема введения дозы антитела к ifnar 1 для подкожной инъекции

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331